Celgene Corp. (CELG)

91.81
0.05 0.05
NASDAQ : Health Technology
Prev Close 91.76
Open 91.70
Day Low/High 91.59 / 91.98
52 Wk Low/High 58.59 / 98.97
Volume 1.41M
Avg Volume 4.92M
Exchange NASDAQ
Shares Outstanding 705.26M
Market Cap 64.83B
EPS 5.70
P/E Ratio 14.04
Div & Yield N.A. (N.A)

Latest News

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

Stocks End Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks

Stocks End Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks

Stocks end little changed Monday as investors look to the upcoming G-20 summit for a breakthrough in talks between the world's two largest economies.

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Let's check out the charts of BMY.

Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal

Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal

Bristol-Myers Squibb slumped to the bottom of the S&P 500 Monday after the group said the U.S. Federal Trade Commission was still looking into its proposed $74 billion takeover of cancer specialist Celgene and that it would sell that company's psoriasis to push the deal through.

Dow Futures Rise, Global Stocks Edge Higher, as US-China Trade Detente Nears

Dow Futures Rise, Global Stocks Edge Higher, as US-China Trade Detente Nears

U.S. stocks look set to test all time highs again Monday, following a third consecutive weekly gain for all three benchmarks on Wall Street, as investors continue to bet that central bank support will boost global equities and this weekend's G20 Summit in Osaka will trigger a breakthrough in U.S.-China trade talks.

Bristol-Myers Squibb Provides Update On Pending Merger With Celgene

Bristol-Myers Squibb Provides Update On Pending Merger With Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company's pending merger with Celgene Corporation (NASDAQ: CELG).

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.

Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs In MS: An Innovation Challenge"

Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs In MS: An Innovation Challenge"

Winner selected for potential of innovation to impact people with multiple sclerosis (MS) and their care partners

The S&P's Death-Zone?

Just like the world's tallest mountains, the S&P 500 can seem to run out of oxygen at the top -- and over 29,000 felt Tuesday like a trip too high -- but there's still room to breathe.

US FDA And EMA Accept Applications For Ozanimod For The Treatment Of Relapsing Forms Of Multiple Sclerosis

US FDA And EMA Accept Applications For Ozanimod For The Treatment Of Relapsing Forms Of Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that the U.S.

Bristol-Myers Squibb Announces Post-Closing Leadership Team

Bristol-Myers Squibb Announces Post-Closing Leadership Team

Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company's pending merger with Celgene Corporation (NASDAQ:CELG).

Celgene Announces Data From Ongoing Studies Of Liso-Cel In Patients With Difficult-to-Treat Blood Cancers At ASCO 2019

Celgene Announces Data From Ongoing Studies Of Liso-Cel In Patients With Difficult-to-Treat Blood Cancers At ASCO 2019

Celgene Corporation (NASDAQ: CELG) today announced that data from the TRANSCEND CLL 004 and TRANSCEND NHL 001 trials studying the investigational anti-CD19 chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel; JCAR017) in...

Celgene Corporation And Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application In Myelodysplastic Syndromes And Beta-Thalassemia

Celgene Corporation And Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application In Myelodysplastic Syndromes And Beta-Thalassemia

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the U.

Celgene Updated Analysis Of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses In Patients Previously Treated For Myelofibrosis With Ruxolitinib

Celgene Updated Analysis Of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses In Patients Previously Treated For Myelofibrosis With Ruxolitinib

Celgene Corporation (NASDAQ: CELG) announced an updated analysis of data from the Phase 2 JAKARTA2 clinical study demonstrating clinically meaningful response rates with investigational fedratinib in patients with myelofibrosis previously treated with...

Celgene Presents Data From A Phase 1/2 Clinical Study Of Iberdomide In Combination With Dexamethasone In Patients With Relapsed And Refractory Multiple Myeloma At ASCO 2019

Celgene Presents Data From A Phase 1/2 Clinical Study Of Iberdomide In Combination With Dexamethasone In Patients With Relapsed And Refractory Multiple Myeloma At ASCO 2019

Celgene Corporation (NASDAQ: CELG) today announced the first clinical results evaluating iberdomide (CC-220) in combination with dexamethasone in patients with relapsed and refractory multiple myeloma from the ongoing phase 1/2 CC-220-MM-001 study during...

Celgene And The Multiple Sclerosis Association Of America Team Up To Launch MS MindShift For Awareness Of Multiple Sclerosis And Brain Health

Celgene And The Multiple Sclerosis Association Of America Team Up To Launch MS MindShift For Awareness Of Multiple Sclerosis And Brain Health

Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) today announced the launch of a new campaign, MS MindShift: A New View of MS, a national initiative that provides new perspective on multiple sclerosis (MS).

Celgene Receives European Commission Approvals For REVLIMID® (lenalidomide) And IMNOVID® (pomalidomide)-based Triplet Combination Regimens For Patients With Multiple Myeloma

Celgene Receives European Commission Approvals For REVLIMID® (lenalidomide) And IMNOVID® (pomalidomide)-based Triplet Combination Regimens For Patients With Multiple Myeloma

Celgene Corporation (NASDAQ:CELG), today announced that the European Commission (EC) has approved two new triplet regimens based on Celgene's proprietary IMiD treatments, REVLIMID (lenalidomide) and IMNOVID (pomalidomide).

Celgene To Highlight New And Updated Hematology And Oncology Clinical Data At Upcoming American Society Of Clinical Oncology (ASCO) 2019 Annual Meeting

Celgene To Highlight New And Updated Hematology And Oncology Clinical Data At Upcoming American Society Of Clinical Oncology (ASCO) 2019 Annual Meeting

Celgene Corporation (NASDAQ: CELG) today announced that data from more than 40 company-sponsored, global alliance and investigator-initiated clinical studies evaluating Celgene's investigational and approved therapies will be presented at the American...

Lyfebulb And Celgene Announce Finalists For 2019 "Addressing Unmet Needs In MS: An Innovation Challenge"

Lyfebulb And Celgene Announce Finalists For 2019 "Addressing Unmet Needs In MS: An Innovation Challenge"

Finalist patient entrepreneurs recognized for potential of innovations in multiple sclerosis (MS)

Jim Cramer: It Isn't a Slowdown That I Fear, It's a Tweet

Jim Cramer: It Isn't a Slowdown That I Fear, It's a Tweet

This is the first time I can ever recall when a president is so attuned to the market that he will bend to its wishes.

Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups In Adults With Relapsing Multiple Sclerosis

Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups In Adults With Relapsing Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced the results of a post-hoc analysis of data from the Phase 3 RADIANCE™ Part B trial showing that ozanimod reduced cortical grey matter volume loss versus first-line treatment, Avonex ® (interferon beta-1a),...

What to Watch Out For: Cramer's 'Mad Money' Recap (Thursday 5/2/19)

What to Watch Out For: Cramer's 'Mad Money' Recap (Thursday 5/2/19)

Jim Cramer says that although a sell-off can breed a buying opportunity, investors need to worry about sky-high IPOs and other signs of froth.

TheStreet Quant Rating: C+ (Hold)